Getting your Trinity Audio player ready... MONTREAL — In hindsight, choosing to undergo eye surgery Nov. 15 and still travel with the Avalanche on this four-game trip was somewhat injudicious. My work ...

Reproxalap significantly reduced ocular redness and increased tear production in DED patients compared to placebo, achieving primary and secondary endpoints. The study involved 57 participants with ...

Reproxalap 0.25% was superior to vehicle-control on ocular discomfort symptom score from 80 to 100 minutes after chamber entry. Reproxalap ophthalmic solution 0.25% reached the primary endpoint in a ...

Aldeyra Therapeutics, Inc. ALDX announced positive data from the vehicle-controlled crossover clinical study which evaluated its investigational product candidate, 0.25% reproxalap ophthalmic solution ...